Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Nivolumab

Diffuse large B-cell-lymphoma

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Takamizawa S, et al. P3-5 DLBCL developed during the immune checkpoint inhibitor therapy in a patient with advanced gastric cancer. Annals of Oncology 34 (Suppl. 3): S1443 abstr. P3-5, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.annonc.2023.09.332 [abstract] Takamizawa S, et al. P3-5 DLBCL developed during the immune checkpoint inhibitor therapy in a patient with advanced gastric cancer. Annals of Oncology 34 (Suppl. 3): S1443 abstr. P3-5, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.annonc.2023.09.332 [abstract]
Metadaten
Titel
Nivolumab
Diffuse large B-cell-lymphoma
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58432-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Colchicine

Case report

Multiple drugs

Case report

Pembrolizumab

Case report

Multiple drugs